Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that Andrew Wright has been appointed as Financial Controller & Company Secretary, a non-Board position, and that Lawrence Pemble, Chief Operating Officer, will step down from the Board, both with immediate effect.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that Andrew Wright has been appointed as Financial Controller & Company Secretary, a non-Board position, and that Lawrence Pemble, Chief Operating Officer, will step down from the Board, both with immediate effect.
Andrew began his career in audit at PricewaterhouseCoopers and has an MBA in Finance and Strategy from the UCLA Anderson School of Management in Los Angeles, USA. He serves as Director of Corporate Development and Technology for Thomas Murray, a post-trade capital markets data and advisory firm. Andrew is also an Executive Director of Trayned Insight Ltd, a data science company serving the healthcare and pharmaceutical industries.
Dr. Vladislav Sandler, CEO of Hemogenyx, commented:
“I am delighted to welcome Andrew to the team and look forward to his support as we continue to advance the development of our novel therapeutic products for patients with blood and severe autoimmune diseases. I would also like to extend my thanks to Lawrence for his contribution to the Board and we wish him well in his next ventures.”
Enquiries:
| Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com | ||||
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | Via Walbrook PR | ||||
| Sir Marc Feldmann, Executive Chairman | |||||
| Northland Capital Partners Limited | Tel: +44 (0)20 3861 6625 | ||||
| Matthew Johnson, Vadim Alexandre, Dugald J Carlean | |||||
| Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 | ||||
| Lucy Williams, Duncan Vasey | |||||
| Walbrook PR (UK Media & Investor Relations) | Tel: +44 (0)20 7933 8780 orhemogenyx@walbrookpr.com | ||||
| Paul McManus | Mob: +44 (0)7980 541 893 | ||||
| US Media enquiries | |||||
| Lowell Goodman | Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com | ||||
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, Hemogenyx LLC, located in Brooklyn, New York at its state-of-the-art research facility (“Hemogenyx”).
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is used only as a last resort and its use is restricted. Hemogenyx’s technology has the potential to enable many more patients suffering from devastating blood diseases, such as leukemia and lymphoma, as well as severe autoimmune diseases, such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.
